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LifBACKGROUND Patients with severe aortic stenosis (AS) who were deemed too high risk or inoperable for conventional
aortic valve replacement (AVR) in the PARTNER (Placement of Aortic Transcatheter Valves) trial were randomized to
transcatheter aortic valve replacement (TAVR) versus AVR (PARTNER-A arm) or standard therapy (PARTNER-B arm).
OBJECTIVES This study compared when and how deaths occurred after TAVR versus surgical AVR or standard therapy.
METHODS The PARTNER-A arm included 244 transfemoral (TF) and 104 transapical (TA) TAVR patients, and 351 AVR
patients; thePARTNER-B arm included 179TF-TAVRpatients and 179 standard therapypatients. Deathswere categorized as
cardiovascular, noncardiovascular, or uncategorizable, and were characterized by multiphase hazard modelling.
RESULTS In the PARTNER-A arm, the risk of death peaked after randomization in the TA-TAVR and AVR groups, falling
to low levels commensurate with the U.S. population within 3 months. Early risk was less in TF-TAVR patients, resulting
in initial superior survival; between 12 and 18 months, risk increased, such that within 2 years, TF-TAVR and AVR patients
had similar survival rates. Cardiovascular, noncardiovascular, and uncategorizable deaths for TF-TAVR were 37%, 43%,
and 20%, respectively, versus 22%, 41%, and 37%, respectively, for TA-TAVR and 33%, 43%, and 24%, respectively, for
AVR. In the PARTNER-B arm, risk with standard therapy was 60% per year; TF-TAVR reduced risk to 20% per year,
resulting in 0.5 years of life added within 2.5 years.
CONCLUSIONS In inoperable AS patients, TAVR substantially reduced the risk of cardiovascular death. In high-risk
patients, TA-TAVR and AVR were associated with elevated peri-procedural risk more than with TF-TAVR, although
cardiovascular death was higher after TF-TAVR. Therefore, TF-TAVR should be considered the standard of care for
severely symptomatic inoperable patients or those at high risk of noncardiovascular mortality after conventional surgery.
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ABB R E V I A T I O N S
AND ACRONYMS
AS = aortic stenosis
AVR = surgical aortic valve
replacement
CL = conﬁdence limit
STS = Society of Thoracic
Surgeons
TA = transapical
TAVR = transcatheter aortic
valve replacement
TF = transfemoral
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159S ymptomatic aortic stenosis (AS) has a dismalprognosis. Despite this, up to two-thirds of pa-tients with severe AS do not undergo surgical
aortic valve replacement (AVR) due to their comor-
bidities (1–6). Thus, after some small, but promising
feasibility studies and trials, the applicability of
transcatheter aortic valve replacement (TAVR) for
these high-risk patients has evolved rapidly
(6–10). The 2-armed randomized PARTNER (Place-
ment of Aortic Transcatheter Valves) trial was
designed to test the procedure for safety and effec-
tiveness. Patients in the PARTNER-A arm were
considered high risk for surgery; patients in
the PARTNER-B arm were considered inoperable.SEE PAGE 169This detailed analysis reports on deaths among pa-
tients in both trial arms, including those that occurred
between randomization and the procedure, focusing
on when and how the deaths occurred (11–14).
METHODS
PATIENTS. A total of 3,105 patients were presented to
a Web-based review panel for potential inclusion
in the PARTNER trial. All patients were required to
have a Society of Thoracic Surgeons (STS) score
of >10%, unless comorbidities that were not part of
the score assessment were present (e.g., radiation
heart disease, cirrhosis, or porcelain calciﬁcation of
the aortic arch without a distal landing site for a
replacement graft). Patients were required to have an
aortic valve area <0.8 cm2 and either a mean trans-
aortic gradient of >40 mm Hg or a transvalvar velocity
of >4.0 m/s (11–14). High-risk patients were required
to have a >15% probability of 30-day mortality, as
deemed by the surgeon, irrespective of the STS score.
Of the reviewed patients, 699 were considered
high risk for open surgery (PARTNER-A), and 358
were considered inoperable (PARTNER-B). Before
randomization, a determination was made as to
whether each patient was suitable for the trans-
femoral (TF) or the transapical (TA) approach. Ofresearch grant support from Medtronic and St. Jude Medical; and consultin
and Entourage. Dr. Guyton has received consultant fees from Medtronic. Dr.
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Manuscript received May 15, 2013; revised manuscript received July 30, 201PARTNER-A patients, 348 were randomized
to TAVR—244 to a TF approach (TF-TAVR)
and 104 to a TA approach (TA-TAVR)
(depending on vascular access)—and 351 were
randomized to AVR (12).
The inoperable PARTNER-B subset was
deﬁned as those patients whowere deemed by
2 cardiac surgeons as having a >50% proba-
bility of death or irreversible severe morbidity
after AVR (11). Of PARTNER-B patients, 179
were randomized to TF-TAVR and 179 to
standard therapy (medical management with
or without balloon aortic valvotomy).Baseline patient characteristics were similar among
subsets of both PARTNER-A and PARTNER-B arms
(11–14). The trial was approved by the U.S. Food and
Drug Administration and the institutional review
board at each participating center. Additional trial
details are described in earlier publications (11–14).
All patients who underwent TAVR received the
Edwards Sapien valve (Edwards Lifesciences, Irvine,
California).
ENDPOINTS. The primary endpoint was all-cause
mortality from time of randomization (intent-
to-treat). The Online Appendix provides analyses of
as-treated mortality in PARTNER-A. Secondary end-
points were categories and subcategories of deaths.
Al l -cause morta l i ty . Median follow-up was 2 years
for PARTNER-A patients, and 10% of the survivors
were followed for more than 3 years; 1,154 patient-
years of follow-up were available for analyses. Me-
dian follow-up was 1.3 years for PARTNER-B patients,
and 10% of the survivors were followed for more than
3.2 years; 541 patient-years of follow-up were avail-
able for analyses. All time-related depictions were
truncated at 2.5 years. Mortality information was
current as of April 25, 2012.
Categor izat ion of deaths . The PARTNER Trial
Clinical Events Committee reviewed documentation
concerning every death that occurred after
randomization, initially blinded according to ran-
domized group, then unblinded. Each death wasg fees from Edwards Lifesciences, Medtronic, Sorin,
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FIGURE 1 All-Cause Mortality in PARTNER-A
(A) Instantaneous risk of death after transcatheter aortic valve replacement (TAVR)
performed either transapically (TA) (blue) or transfemorally (TF) (salmon), and surgical
aortic valve replacement (AVR) (red). For reference, ﬁne dash-dot-dash lines represent
risk of death in an age-, sex-, and race-matched U.S. population. (B) Survival stratiﬁed by
randomized groups. Each symbol represents a death, vertical bars are 68% conﬁdence
limits (CL) equivalent to 1 SE, and numbers beneath the horizontal axis are
patients remaining at risk. Solid lines represent parametric survival estimates. Fine dash-
dot-dash lines represent survival of an age-, sex-, and race-matched U.S. population.
(C) Estimated lifetime gained by TF-TAVR over AVR. This represents the integrated
difference between TF-TAVR and AVR survival curves in Figure 1B. Dashed lines form a
90% conﬁdence band.
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160placed into 1 of 3 categories: 1) clearly cardiovas-
cular in cause, mechanism, and circumstance (mode
of death); 2) clearly noncardiovascular in cause,
mechanism, and circumstance; or 3) not clearly
classiﬁable as 1 or the other of these 2 categories.
Two of the authors (N.B. and L.G.S.) reviewed
the medical records of uncategorizable patients,
often ﬁnding they were elderly and frail, and
failed to thrive. This admixture of unfavorable
demographic characteristics, and cardiovascular
and noncardiovascular comorbidities, as well as
circumstances that surround many deaths in hos-
pice care and skilled nursing facilities, made it
impossible to classify these deaths as clearly car-
diovascular or noncardiovascular, despite extensive
documentation.
Cardiovascular deaths were further subcategorized
as due to heart failure, sudden death, stroke,
arrhythmia, myocardial infarction, noncerebral hem-
orrhage, endocarditis of prosthetic study valve,
arterial disease, vascular complications, other, or un-
known. Noncardiovascular deaths were further sub-
categorized as due to infection, cancer, renal disease,
accident, pulmonary disease, other, or unknown.
Two of the authors (N.B. and L.G.S.) reviewed the
deaths for potential valve-related causes and per-
formed a more detailed evaluation of the “other”
subcategory.
DATA ANALYSIS. All analyses were performed
using SAS statistical software (SAS version 9.2,
SAS, Inc., Cary, North Carolina). The starting point for
all analyses of death was time of randomization.
Survival after randomization was estimated non-
parametrically by the Kaplan-Meier estimator and
parametrically by a multiphase, temporal decompo-
sition hazard model (15). Parametric modeling
resolved a number of phases of instantaneous risk
of an event (hazard function), mathematical equa-
tions used to characterize these phases, and values
of shaping parameters.
For reference, U.S. Life Tables (National Center
for Health Statistics, Hyattsville, Maryland) were
used to construct conditional survival and risk of
death according to each patient’s age, sex, and race.
These individual survival estimates were averaged
across time to yield matched population-based ex-
pected survival and hazard curves. Years gained
by 1 therapy versus another were calculated by
the difference between survival curves, integrated
across time (16).
Categories of death represented competing risks.
Nonparametric estimates and conﬁdence limits (CLs)
of competing risks used the methods described by
Anderson et al. (17). Parametric estimates were
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FIGURE 2 All-Cause Mortality in PARTNER-B
(A) Instantaneous risk of death among patients randomized to standard
therapy (red) or TF-TAVR (blue). Format is as in Figure 1A. (B) Survival
stratiﬁed by randomized groups. Format is as in Figure 1B. (C) Estimated
lifetime gained by TF-TAVR over standard therapy. This represents the inte-
grated difference between TF-TAVR and standard therapy survival curves in
Figure 2B. Dashed lines form a 90% conﬁdence band. Abbreviations as in
Figure 1.
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161obtained by numerical integration of the individual
parametric hazard estimates for each competing risk.
Presentat ion . Actuarial and instantaneous risk of
death estimates are accompanied by asymmetric
conﬁdence intervals equivalent to 1 SE (68% conﬁ-
dence coefﬁcient). The integrated difference between
survival curves is accompanied by 90% conﬁdence
bands to obtain a similar visual interpretation as
an overlapping 68% CL (16). Comparisons of causes
of death among the randomized groups were made
using a chi-square test of independence. Fisher’s
exact test was used when comparing 2 groups with a
cell frequency <5.
RESULTS
OVERALL RISK OF DEATH. The PARTNER-A Tr ia l .
At the date of the last follow-up (April 25, 2012), 275
PARTNER-A patients had died, 20 of them between
randomization and the procedure (Online Fig. 9).
Instantaneous unadjusted risk of death peaked
early after randomization in both AVR and TA-
TAVR groups, falling within 3 to 6 months to a
low level commensurate or better than that of
the matched U.S. population estimates (Fig. 1A).
Seventeen deaths occurred before the procedure in
the AVR group (4.8%) and 1 in the TA-TAVR group
(1.0%). The magnitude and longer duration of the
early hazard in the AVR group was partly related
to these deaths before surgery during the more
prolonged interval between randomization and the
procedure (median 9 days, with a lengthy right tail)
compared with either TAVR subgroup (median
7 days, with a shorter right tail) (Online Fig. 11). In
contrast to an early peaking hazard, risk after ran-
domization to TF-TAVR was only modestly elevated
after the date of randomization, and gradually fell
over the ﬁrst year of follow-up to levels similar to
that of the other 2 groups. Two deaths occurred
before the procedure (0.8%). This pattern of early
risk resulted in separation of the TF-TAVR survival
curves from the survival curves of AVR and
TA-TAVR (Fig. 1B).
After approximately 3 months, instantaneous risk
became constant in the TA-TAVR subgroup, but
gradually rose after approximately 1.5 years in the
TF-TAVR group and after approximately 1 year in
the AVR group. This resulted in nearly parallel
survival curves for TA-TAVR and TF-TAVR, with
survival of the AVR group between them. TF and TA
subsets of the AVR group had similar temporal risk
proﬁles (Online Fig. 1). A total of 0.13 years (90%
CL: 0.008 to 0.27) of lifetime was gained within
2.5 years by the TF-TAVR group over the AVR group(Fig. 1C), 0.22 years (90% CL: 0.025 to 0.41) by
the TF-TAVR group over the TA-TAVR group
(Online Fig. 2), and 0.087 years (90% CL: 0.102
to 0.28) by the AVR group over the TA-TAVR group
(Online Fig. 3).
TABLE 1 Categorization of Deaths in PARTNER-A Patients
Mode of Death
TF-TAVR TA-TAVR AVR
p ValueN n (%) N n (%) N n (%)
Cardiovascular 33 10 46
Heart failure 13 (39) 4 (40) 16 (35) 0.90
Sudden death 9 (27) 1 (10) 12 (26) 0.50
Arrhythmia 1 (3) 3 (30) 5 (11) 0.05
Stroke 5 (15) 0 (0) 7 (15) 0.40
Noncerebral
hemorrhage
1 (3) 1 (10) 2 (4.3) 0.60
Myocardial infarction 1 (3) 0 (0) 1 (2.2) 0.80
Prosthetic valve
endocarditis
0 (0) 1 (10) 1 (2.2) 0.20
Peripheral arterial
disease or abdominal
aortic aneurysm
1 (3) 0 (0) 0 (0) 0.40
Vascular complication 1 (3) 0 (0) 0 (0) 0.40
Other 1 (3) 0 (0) 1 (2.2) 0.80
Unknown 0 (0) 0 (0) 1 (2.2) 0.60
Noncardiovascular 39 19 60
Infection/sepsis 15 (38) 7 (37) 28 (47) 0.60
Renal disease 6 (15) 0 (0) 6 (10) 0.20
Malignancy 4 (10) 1 (5.3) 8 (13) 0.60
Accidental 3 (7.7) 0 (0) 1 (1.7) 0.20
Respiratory 3 (7.7) 7 (37) 9 (15) 0.02
Other 8 (20) 2 (10) 7 (12) 0.50
Unknown 0 (0) 2 (11) 1 (1.7) 0.05
Uncategorizable 18 17 33
AVR ¼ surgical aortic valve replacement; TA-TAVR ¼ transapical transcatheter
aortic valve replacement; TF-TAVR ¼ transfemoral transcatheter aortic valve
replacement.
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162The PARTNER-B Tr ia l . At the date of last follow-
up, 237 PARTNER-B patients had died, 2 between
randomization and TF-TAVR (1.1%). For patients
randomized to TF-TAVR, the pattern of instanta-
neous risk of death paralleled that of TF-TAVR
for PARTNER-A patients, although at a somewhat
higher level (Fig. 2A). Those randomized to stan-
dard therapy, however, exhibited an early peak—
possibly related to balloon aortic valvotomy—that
was prolonged beyond 6 months and merged with
a constant hazard that was considerably higher
than that after TF-TAVR, and higher than that
expected for the general population. Thus, survival
diverged between the 2 trial arms within 30 to
60 days, and the gap widened thereafter (Fig. 2B).
The net lifetime added by TF-TAVR over standard
therapy was 0.50 years (90% CL: 0.30 to 0.67)
(Fig. 2C).
Reference to genera l populat ion . Instantaneous
risk of death early after randomization was consid-
erably higher among all intervention groups than
that referenced to an age-, sex, and race-matched
population life table (Online Fig. 4A). As a result,
survival was immediately less than that expected
of the general population (Online Fig. 4B). Howev-
er, between 6 and 18 months, risk of death rapidly
decreased in these groups to near or below the
level expected for the general population. There-
after, risk of death began to rise above that of the
general population. This temporal pattern of risk
contrasted with standard therapy patients, who
remained at considerably higher risk than that of
the general population throughout the 2.5 years of
follow-up.
CARDIOVASCULAR VERSUS NONCARDIOVASCULAR
DEATHS. The PARTNER-B Tr ia l . Among PARTNER-
A patients, death was categorized as cardiovascu-
lar in 89 patients, noncardiovascular in 118, and
uncategorizable in 68 (Table 1, Online Table 1). In-
stantaneous risk of cardiovascular death peaked
earlier after randomization to TF-TAVR than to AVR
(Fig. 3A). Instantaneous risk of noncardiovascular
death also peaked after randomization, but the peak
was higher and earlier in the AVR group than in either
the TA-TAVR or TF-TAVR groups (Fig. 3B, Online
Figs. 5A to 5C). Of deaths between randomization
and procedure, 2 in the TF-TAVR group were cardio-
vascular (arrhythmia and heart failure), and 1 death
in the TA-TAVR group was uncategorizable (Online
Appendix). Of the 17 deaths in the AVR group, 8
were cardiovascular (2 arrhythmia, 4 heart failure, 2
sudden), 5 were noncardiovascular (2 infection, 1 renal
failure, 1 encephalopathy, 1 necrotic bowel), and 4
were uncategorizable.The PARTNER-B Tr ia l . Among PARTNER-B pa-
tients, death was categorized as cardiovascular in 107
patients, noncardiovascular in 53, and uncategoriz-
able in 77 (Table 1, Online Table 2). Instantaneous risk
of cardiovascular death during standard therapy
remained elevated well above risk after randomiza-
tion to TF-TAVR (Fig. 4A, Online Figs. 6A and 6B).
Risk of cardiovascular death peaked early after TF-
TAVR, fell to lower levels within approximately 6
months, and gradually rose after approximately 1
year, similar to that observed in PARTNER-A patients
(Online Fig, 7A). Although risk of noncardiovascular
death peaked after randomization to TF-TAVR, the
general level of risk was similar to that of standard
therapy (Fig. 4B) and noncardiovascular death in
PARTNER-A patients (Online Fig. 7B). One death be-
tween randomization and intended TF-TAVR was due
to heart failure, and 1 was uncategorizable.
SUBCATEGORIES OF CARDIOVASCULAR DEATH.
The 2 most common subcategories of cardiovascular
death among PARTNER patients were heart failure
and sudden death (Tables 1 and 2). Risk of death
from heart failure after TAVR or AVR peaked early
TF-TAVR
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AVR
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FIGURE 3 Instantaneous Risk of Cardiovascular and Noncardiovascular
Death After TAVR Performed Either TA or TF Versus Surgical AVR in
PARTNER-A
Format is as in Figure 1A, except that dashed lines enclosing the solid para-
metric hazard estimates form a 68% conﬁdence band. (A) Cardiovascular
death. (B) Noncardiovascular death. Blue ¼ TA; salmon ¼ TF; red ¼ AVR.
Abbreviations as in Figure 1.
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163after the procedure (Fig. 5A), unlike that for sudden
death (Fig. 5B). In PARTNER-B patients, the risk
was more protracted, but risk of death from heart
failure remained elevated during standard therapy
(Fig. 6A). Risk of sudden death occurred at a low level
among patients randomized to an aortic valve inter-
vention in both PARTNER-A and PARTNER-B.
However, risk was considerably higher and remained
elevated in patients randomized to standard therapy
(Fig. 6B).
SUBCATEGORIES OF NONCARDIOVASCULAR DEATH.
The most common subcategories of noncardiovas-
cular death among PARTNER patients were infec-
tion, respiratory complications, and malignancies
(Tables 1 and 2). There were 24 noncardiovascular
deaths in the “other” category: 8 from neurological
events, 2 from multisystem organ failure, 5 from liver
failure, 7 from gastrointestinal complications, and 2
from uncertain noncardiovascular causes (Table 3).
Close examination of clinical source documents
from PARTNER-B patients whose deaths could not be
categorized showed that they were later deaths that
occurred in nursing homes or hospices, were associ-
ated with old age, frailty, or failure to thrive, and
could not be further characterized.
DEVICE-RELATED DEATHS. No device failure
occurred in either PARTNER-A or -B. In the entire
PARTNER study, there were 4 deaths from endocardi-
tis, all involving a prosthetic valve (Tables 1 and 2).
There were no deaths from hemolysis; only 1 pa-
tient experienced documented hemolysis, and that
was after AVR.
DISCUSSION
OVERALL RISK OF DEATH. Tempora l Pattern of
Ri sk . The instantaneous risk of death (hazard func-
tion) following intervention is initially high, then falls
to a low level before gradually rising (Central
Illustration). This “bathtub-shaped” risk following
open cardiac surgical procedures has been observed
for several decades (15,18–20). Clinical management
of patients after surgery mirrors this pattern of
risk: intensive care, step-down unit, regular nursing
ﬂoor, and discharge to a nearby hotel or home.
Nevertheless, the period of higher risk extends
well beyond initial hospitalization, as was found in
the present study. This corresponds with elevated
risk of hospital readmissions soon after hospital
discharge.
However, an important novel ﬁnding is that early
risk after randomization to TF-TAVR in PARTNER-A
and -B was substantially lower than after TA-TAVR
or AVR. Thus, an advantage of a percutaneousapproach is a reduction of peri-procedural risk,
particularly noncardiovascular risk.
The shape of the elevated early hazard phase is not
typical of that previously found for surgical inter-
vention, in that it peaks for the surgical cohorts.
Generally, risk is highest immediately after a proce-
dure, then falls steeply. The explanation lies in the
nature of this intent-to-treat analysis. The interval
between randomization and the procedure has a
lengthy “right tail” of up to several weeks or months.
The peaking early hazard phase is a result, as dem-
onstrated when an “as treated” analysis of instanta-
neous risk is performed (Online Fig. 12A): the
peak disappears, and risk starts high immediately
after the procedure. Thereafter, the contour of the
TABLE 2 Categorization of Deaths in PARTNER-B Patients
Mode of Death
Standard
Therapy TF-TAVR
p ValueN n (%) N n (%)
Cardiovascular 67 40
Heart failure 34 (51) 13 (33) 0.07
Sudden death 21 (31) 4 (10) 0.02
Arrhythmia 4 (6) 1 (2.5) 0.60
Stroke 4 (6) 7 (18) 0.10
Noncerebral hemorrhage 2 (3) 0 (0) 0.50
Myocardial infarction 0 (0) 2 (5) 0.14
Prosthetic valve endocarditis 0 (0) 2 (5) 0.14
Peripheral arterial disease/
abdominal aortic aneurysm
0 (0) 1 (2.5) 0.40
Vascular complication 0 (0) 3 (7.5) 0.05
Other 1 (1.5) 2 (5) 0.60
Unknown 1 (1.5) 5 (12) 0.02
Noncardiovascular 21 32
Infection/sepsis 7 (33) 10 (31) >0.90
Renal disease 3 (14) 3 (9.4) 0.70
Malignancy 4 (19) 4 (13) 0.70
Accidental 0 (0) 2 (6.3) 0.50
Respiratory 3 (14) 5 (16) >0.90
Other 1 (4.8) 6 (19) 0.20
Unknown 3 (14) 2 (6.3) 0.40
Uncategorizable 47 30
Abbreviations as in Table 1.
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164hazard function is similar to the depiction shown in
Figure 1A.
In addition, the magnitude of early risk after
randomization to AVR reﬂects 4.8% mortality in
this group before surgery. This contrasts with 0.9%
mortality between randomization and TAVR in the
combined PARTNER trial arms. In observational sur-
gical studies that nearly always commence at opera-
tion, deaths before planned surgery are rarely
reported. This is in contrast to inception cohort
studies, such as randomized trials and some studies
on managing congenital heart disease (21). Bavaria
et al. (22) reported a 12% mortality between referral
for TAVR and procedure in their program, and others
reported even higher mortality for patients screened
for possible valve replacement (23,24).
Relat ion to r i sk in the genera l populat ion . After
early high risk falls to its lowest level, risk of death
is commensurate with that of the age-, sex-, andrace-matched general population. Thereafter, it
gradually begins to rise above that expected in the
general population. In these elderly patients, this
rise is also accelerated beyond that expected in
the general population. Patient demographic charac-
teristics, comorbidities, and new health problems
(e.g., strokes) likely contribute to the post-recovery
increase in risk. These contrast sharply with the
rates observed after surgical reports of AVR, for
which instantaneous risk of death is progressively
less than that of the general population as patient
age increases (20), which is probably due to the selec-
tion of lower risk patients for conventional heart
surgery.
Value of intervent ion . Survival results of the
PARTNER-B randomized trial reported previously
(11–14), and evaluated further in this study, demon-
strate that inoperable patients treated by TF-TAVR
have markedly improved overall survival compared
with standard therapy. This was true despite all of the
conditions, valve- and non–valve-related, that led
to the consensus about inoperability. In this group,
TF-TAVR provided, on average, a half-year of added
lifetime within 2.5 years of randomization. Hence,
TF-TAVR should be considered the standard of care
for inoperable patients with anticipated longevity
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165commensurate with, or better than, that of the gen-
eral population.
CARDIOVASCULAR AND NONCARDIOVASCULAR
DEATHS. After an early phase of high risk attribut-
able mainly to cardiovascular deaths, risk
of cardiovascular death was substantially reduced
in patients randomized to AVR by either TAVR or
AVR compared with those randomized to standard
therapy. In contrast, the risk of noncardiovascular
death was only modestly greater in those random-
ized to standard therapy, because of the comorbid-
ities that made them inoperable. As might be
anticipated, after the early phase of risk, inoperable
PARTNER-B patients randomized to TF-TAVR did
not do as well as high risk PARTNER-A patients
randomized to TF-TAVR. However, the increased
risk of death was related to a higher risk of non-
cardiovascular death.
Although device failure did not occur in either
PARTNER-A or -B, peri-valvar leakage or central
regurgitation could increase the risk of heart failure,
endocarditis, stroke, hemolysis, and death. An in-
creased risk of death related to peri-valvar leakage
has been documented (13), but the etiology needs to
be evaluated further.
SUBCATEGORIES OF CARDIOVASCULAR AND NON-
CARDIOVASCULAR DEATHS. After valve insertion,
the primary mode of death was acute or subacute
heart failure as documented for surgical AVR (19).
It was curious that risk of death in heart failure
gradually diminished among patients randomized to
standard therapy. There were an insufﬁcient number
of patients who crossed over to TAVR or AVR to
account for this; however, the uncategorizable
deaths might explain this trend (Online Figs. 8A to
8F). This could also be due to a Darwinian phe-
nomenon: over time, those individuals whose sur-
vival was most sensitive to their heart disease were
eliminated early from the population, leaving a more
robust group.
Although sudden death still occurred occasionally
after TAVR and AVR, it continued unabated at nearly
10% per year among patients randomized to standard
therapy. Thus, AVR distinctly reduced risk of sudden
death and heart failure death.
STUDY LIMITATIONS. Although this was a random-
ized trial with nearly complete follow-up, blinded
adjudication of adverse events, and meticulous
assessment, minor factors might have inﬂuenced the
outcomes. Comorbid variables were generally well-
balanced, but there were small differences of un-
known clinical consequence (11–14). Treated TAVR
patients might have been followed and managedmore intensively, because this was not a blinded
treatment study. Clearly, these patients represented
a selected population who underwent rigorous
screening. Only one-third of screened patients were
enrolled (11), and approximately 12% of patients pre-
sented to the Web-based review panel for potential
inclusion were eventually randomized. Whether
these results could be generalized to patients at in-
stitutions beyond those participating in this trial is
not known.
It was beyond the scope of this study to translate
added lifetime from TAVR over standard therapy to
quality-adjusted life years (25), a necessary step in
assessing cost effectiveness of treatments. In addi-
tion, we did not perform a multivariable analysis
of death to identify risk factors for both early and
late deaths in the various patient subsets. Thus, we
did not address the possibility that some patients
beneﬁtted more than others from intervention.
These are subjects of forthcoming investigations.
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TABLE 3 Other Noncardiovascular Deaths
Mode of Death
PARTNER-A
TF-TAVR
(N ¼ 8)
TA-TAVR
(N ¼ 2)
AV
(N ¼
Neurological 3 (38) 1 (50) 2 (2
Dementia 1 1 0
Intracranial hemorrhage 1 0 0
Encephalopathy 0 0 2
Parkinsonism 0 0 0
Other 1 0 0
Gastrointestinal 2 (25) 0 (0) 2 (2
Bleed 1 0 1
Bowel obstruction 1 0 1
Necrotic bowel 0 0 0
Multisystem organ failure 0 (0) 1 (50) 1 (1
Liver failure 2 (25) 0 (0) 2 (2
Uncertain 1 (12) 0 (0) 0 (
Values are n (%).
Abbreviations as in Table 1.
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166Similarly, the effects of balloon aortic valvotomy and
crossover in the standard therapy group were not
examined.
Although death was a hard endpoint, categoriza-
tion of the circumstances surrounding each death,
particularly the mechanism of death, was subjective,
and the data were incomplete. Few autopsies were
performed to identify possible mechanisms. This
resulted in a substantial proportion of deaths deemed
as uncategorizable.
Procedural aspects of TAVR, peri-operative neuro-
logical events, and vascular access site issues were
the focus of previous reports. This study did not
speciﬁcally address these problems and their possible
effects on mortality (26–30).
CONCLUSIONS
In inoperable AS patients, TAVR substantially reduced
risk of cardiovascular death. In high-risk patients, TA-
TAVR and AVR were associated with elevated peri-
procedural risk more than TF-TAVR, particularly for
noncardiovascular death, although early risk of car-
diovascular death was higher with TF-TAVR. There-
fore, TF-TAVR should be considered the standard
of care for eligible inoperable patients with severe
symptomatic AS or at high risk of noncardiovascular
mortality after conventional surgery.
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R
7) p Value
Standard
(N ¼ 1)
TF-TAVR
(N ¼ 6) p Value
9) 0.80 0 (0) 2 (33) >0.90
0 1
0 0
0 0
0 1
0 0
9) 0.70 1 (100) 2 (33) >0.90
1 1
0 0
0 1
4) 0.20 0 (0) 0 (0) >0.90
9) 0.70 0 (0) 1 (17) >0.90
0) >0.90 0 (0) 1 (17) >0.90
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: After an
early high-risk phase following the procedures, the risk of
cardiovascular death was lower in patients undergoing
TAVR or surgical AVR than those managed without valve
replacement. In high-risk patients, TAVR should therefore
be considered for severely symptomatic inoperable pa-
tients or those at high risk of noncardiovascular mortality
after surgical AVR.
TRANSLATIONAL OUTLOOK 1: Registry studies could
provide insight into the generalizability of the beneﬁt of
TAVR to patients with severe aortic stenosis outside the
context of a randomized trial.
TRANSLATIONAL OUTLOOK 2: Additional studies are
needed to reveal risk factors for early and late mortality
after TAVR and identify patients such as those with
cardiac cachexia (characterized by low body mass index
and hypoalbuminemia) for whom intervention may be
futile.
CENTRAL ILLUSTRATION Composite Instantaneous Risk of Cardiovascular and Noncardiovascular Death in PARTNER-A and -B
AVR ¼ aortic valve replacement; TA ¼ transapically; TAVR ¼ transcatheter aortic valve replacement; TF ¼ transfemorally.
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